610 related articles for article (PubMed ID: 12405865)
1. Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence.
Eap CB; Buclin T; Baumann P
Clin Pharmacokinet; 2002; 41(14):1153-93. PubMed ID: 12405865
[TBL] [Abstract][Full Text] [Related]
2. [Methadone: from pharmacokinetic profile to clinical pharmacology].
Vazquez V; Gury C; Laqueille X
Encephale; 2006; 32(4 Pt 1):478-86. PubMed ID: 17099560
[TBL] [Abstract][Full Text] [Related]
3. Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment.
Crettol S; Déglon JJ; Besson J; Croquette-Krokkar M; Gothuey I; Hämmig R; Monnat M; Hüttemann H; Baumann P; Eap CB
Clin Pharmacol Ther; 2005 Dec; 78(6):593-604. PubMed ID: 16338275
[TBL] [Abstract][Full Text] [Related]
4. High-dose morphine and methadone in cancer patients. Clinical pharmacokinetic considerations of oral treatment.
Säwe J
Clin Pharmacokinet; 1986; 11(2):87-106. PubMed ID: 3514045
[TBL] [Abstract][Full Text] [Related]
5. Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19.
Gerber JG; Rhodes RJ; Gal J
Chirality; 2004 Jan; 16(1):36-44. PubMed ID: 14628297
[TBL] [Abstract][Full Text] [Related]
6. Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone.
Kharasch ED; Hoffer C; Whittington D; Sheffels P
Clin Pharmacol Ther; 2004 Sep; 76(3):250-69. PubMed ID: 15371986
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetics of (R)-, (S)- and rac-methadone in methadone maintenance patients.
Foster DJ; Somogyi AA; White JM; Bochner F
Br J Clin Pharmacol; 2004 Jun; 57(6):742-55. PubMed ID: 15151520
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and pharmacodynamics of methadone enantiomers after a single oral dose of racemate.
Boulton DW; Arnaud P; DeVane CL
Clin Pharmacol Ther; 2001 Jul; 70(1):48-57. PubMed ID: 11452244
[TBL] [Abstract][Full Text] [Related]
9. ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment.
Crettol S; Déglon JJ; Besson J; Croquette-Krokar M; Hämmig R; Gothuey I; Monnat M; Eap CB
Clin Pharmacol Ther; 2006 Dec; 80(6):668-81. PubMed ID: 17178267
[TBL] [Abstract][Full Text] [Related]
10. Plasma concentrations of the enantiomers of methadone and therapeutic response in methadone maintenance treatment.
Eap CB; Bourquin M; Martin J; Spagnoli J; Livoti S; Powell K; Baumann P; Déglon J
Drug Alcohol Depend; 2000 Dec; 61(1):47-54. PubMed ID: 11064183
[TBL] [Abstract][Full Text] [Related]
11. Increased (R)-methadone plasma concentrations by quetiapine in cytochrome P450s and ABCB1 genotyped patients.
Uehlinger C; Crettol S; Chassot P; Brocard M; Koeb L; Brawand-Amey M; Eap CB
J Clin Psychopharmacol; 2007 Jun; 27(3):273-8. PubMed ID: 17502774
[TBL] [Abstract][Full Text] [Related]
12. Cytochrome P4503A4 metabolic activity, methadone blood concentrations, and methadone doses.
Shinderman M; Maxwell S; Brawand-Amey M; Golay KP; Baumann P; Eap CB
Drug Alcohol Depend; 2003 Mar; 69(2):205-11. PubMed ID: 12609702
[TBL] [Abstract][Full Text] [Related]
13. Modulation of the central nervous effects of levomethadone by genetic polymorphisms potentially affecting its metabolism, distribution, and drug action.
Lötsch J; Skarke C; Wieting J; Oertel BG; Schmidt H; Brockmöller J; Geisslinger G
Clin Pharmacol Ther; 2006 Jan; 79(1):72-89. PubMed ID: 16413243
[TBL] [Abstract][Full Text] [Related]
14. Methadone dose in heroin-dependent patients: role of clinical factors, comedications, genetic polymorphisms and enzyme activity.
Mouly S; Bloch V; Peoc'h K; Houze P; Labat L; Ksouda K; Simoneau G; Declèves X; Bergmann JF; Scherrmann JM; Laplanche JL; Lepine JP; Vorspan F
Br J Clin Pharmacol; 2015 Jun; 79(6):967-77. PubMed ID: 25556837
[TBL] [Abstract][Full Text] [Related]
15. Steady-state pharmacokinetics of (R)- and (S)-methadone in methadone maintenance patients.
Foster DJ; Somogyi AA; Dyer KR; White JM; Bochner F
Br J Clin Pharmacol; 2000 Nov; 50(5):427-40. PubMed ID: 11069437
[TBL] [Abstract][Full Text] [Related]
16. When "enough" is not enough: new perspectives on optimal methadone maintenance dose.
Leavitt SB; Shinderman M; Maxwell S; Eap CB; Paris P
Mt Sinai J Med; 2000; 67(5-6):404-11. PubMed ID: 11064491
[TBL] [Abstract][Full Text] [Related]
17. Interindividual variability of methadone response: impact of genetic polymorphism.
Li Y; Kantelip JP; Gerritsen-van Schieveen P; Davani S
Mol Diagn Ther; 2008; 12(2):109-24. PubMed ID: 18422375
[TBL] [Abstract][Full Text] [Related]
18. Effects of cytochrome P450 single nucleotide polymorphisms on methadone metabolism and pharmacodynamics.
Ahmad T; Valentovic MA; Rankin GO
Biochem Pharmacol; 2018 Jul; 153():196-204. PubMed ID: 29458047
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and pharmacodynamics of methadone enantiomers after coadministration with fosamprenavir-ritonavir in opioid-dependent subjects.
Cao YJ; Smith PF; Wire MB; Lou Y; Lancaster CT; Causon RC; Bigelow GE; Martinez E; Fuchs EJ; Radebaugh C; McCabe S; Hendrix CW
Pharmacotherapy; 2008 Jul; 28(7):863-74. PubMed ID: 18576901
[TBL] [Abstract][Full Text] [Related]
20. Clinical pharmacokinetics of mirtazapine.
Timmer CJ; Sitsen JM; Delbressine LP
Clin Pharmacokinet; 2000 Jun; 38(6):461-74. PubMed ID: 10885584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
